Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
- PMID: 26956148
- PMCID: PMC4784379
- DOI: 10.1186/s12872-016-0222-6
Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
Abstract
Background: Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical setting.
Methods: The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period of 12 months. There were two principal objectives: 1) documentation of the achievement of target BP values set according to recent national and international guidelines, and 2) description of the safety profile of AZL-M.
Results: A total of 3 849 patients with essential arterial hypertension were recruited from primary care offices in Germany. Patients who initiated monotherapy at baseline comprising either AZL-M or an ACE-inhibitor were included at a ratio of seven to three. Results demonstrated that a blood pressure target of <140/90 mmHg was achieved by a significantly greater proportion of patients in the AZL-M group (61.1 %) compared with the ACE-inhibitor group (56.4 %; p < 0.05; OR, 1.21; 95 % CI, 1.03-1.42), with this finding maintained after adjusting for differences in baseline characteristics. AZL-M appeared to have an equivalent safety profile to the ACE-inhibitors, with a similar incidence of adverse events in the two patient groups (p = 0.73).
Conclusions: These data add to the results of previous randomized controlled clinical trials suggesting that, compared with other agents that target the renin-angiotensin system, AZL-M provides statistically significant albeit small improvements in blood pressure control.
Figures




Similar articles
-
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8. Trials. 2015. PMID: 26686682 Free PMC article.
-
Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):225-233. doi: 10.1111/bcpt.12800. Epub 2017 Jun 19. Basic Clin Pharmacol Toxicol. 2017. PMID: 28444983 Review.
-
EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.BMC Cardiovasc Disord. 2013 Jul 2;13:46. doi: 10.1186/1471-2261-13-46. BMC Cardiovasc Disord. 2013. PMID: 23819631 Free PMC article. Clinical Trial.
-
Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.J Clin Hypertens (Greenwich). 2015 Dec;17(12):947-53. doi: 10.1111/jch.12603. Epub 2015 Jun 24. J Clin Hypertens (Greenwich). 2015. PMID: 26105590 Free PMC article.
-
Azilsartan medoxomil for the treatment of hypertension.Drugs Today (Barc). 2011 Sep;47(9):647-51. doi: 10.1358/dot.2011.47.9.1688573. Drugs Today (Barc). 2011. PMID: 21971539 Review.
Cited by
-
Azilsartan: Current Evidence and Perspectives in Management of Hypertension.Int J Hypertens. 2019 Nov 3;2019:1824621. doi: 10.1155/2019/1824621. eCollection 2019. Int J Hypertens. 2019. PMID: 31885897 Free PMC article. Review.
-
A Pilot Study on the Effect of Angiotensin Receptor Blockers on Platelet Aggregation in Hypertensive Patients- A Prospective Observational Study.J Clin Diagn Res. 2016 Nov;10(11):FC14-FC16. doi: 10.7860/JCDR/2016/21743.8881. Epub 2016 Nov 1. J Clin Diagn Res. 2016. PMID: 28050394 Free PMC article.
-
Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations.Vasc Health Risk Manag. 2022 Jul 11;18:507-515. doi: 10.2147/VHRM.S337640. eCollection 2022. Vasc Health Risk Manag. 2022. PMID: 35846737 Free PMC article. Review.
-
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.Front Pharmacol. 2016 Aug 3;7:235. doi: 10.3389/fphar.2016.00235. eCollection 2016. Front Pharmacol. 2016. PMID: 27536242 Free PMC article. Review.
-
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.J Renin Angiotensin Aldosterone Syst. 2018 Jul-Sep;19(3):1470320318795000. doi: 10.1177/1470320318795000. J Renin Angiotensin Aldosterone Syst. 2018. PMID: 30175930 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous